Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Multiple Myeloma 242Neoplasms, Plasma Cell 50Lymphoma 45Lymphoma, Mantle-Cell 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Lymphoma, Non-Hodgkin 30Recurrence 29Lymphoma, Follicular 24Leukemia, Myeloid, Acute 24Lymphoma, Large B-Cell, Diffuse 23Waldenstrom Macroglobulinemia 22Lymphoma, B-Cell, Marginal Zone 20Leukemia 20Immunoglobulin Light-chain Amyloidosis 18Leukemia, Lymphocytic, Chronic, B-Cell 14Myelodysplastic Syndromes 12Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Hodgkin Disease 11Burkitt Lymphoma 10Breast Neoplasms 10Lymphoma, T-Cell, Peripheral 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, B-Cell 9Lung Neoplasms 9Immunoblastic Lymphadenopathy 9Hematologic Neoplasms 9Prostatic Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell 8

Interventions

gallium Ga 68 dotatate 5Everolimus 5lanreotide 3cabozantinib 3Nivolumab 3pasireotide 2lutetium Lu 177 dotatate 2Temozolomide 2Sunitinib 2Octreotide 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2zimberelimab 1veliparib 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1nintedanib 1ibrutinib 1ganitumab 1fluorodopa F 18 1carfilzomib 1aflibercept 1Sorafenib 1Somatostatin 1Serotonin 1Ramucirumab 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoid Tumor × Bortezomib × Clear all
NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡